ROCKVILLE, Md., Nov. 22, 2022 (GLOBE NEWSWIRE) — Supernus Pharmaceuticals, Inc. (Nasdaq: SUPN) is a biotech company focused on developing and commercializing products for the treatment of central nervous system (CNS) disorders. A pharmaceutical company, announced today. That Jack Khattar, president and CEO of Supernus Pharmaceuticals, joined Piper his fireside chat at Sandler 34 and plans to host an investor meeting.th Annual Healthcare Conference on Tuesday, November 29, 2022 at 10:30 AM ET.
The conference will take place November 29-December 1, 2022 at the Lotte New York Palace in New York City. Investors interested in arranging a meeting with company management should contact the Piper Sandler Conference Coordinator. Fireside Chat’s live audio webcast can be accessed by visiting Events and Presentations in the Investor Relations section of the company’s website at www.supernus.com. An archived replay of the webcast will be available on our website for 60 days after the conference.
About Supernas Pharmaceuticals
Supernus Pharmaceuticals is a biopharmaceutical company focused on the development and commercialization of products for the treatment of central nervous system (CNS) disorders.
Our diverse neuroscience portfolio includes epilepsy, migraine, ADHD, motor dysfunction in Parkinson’s disease (PD), cervical dystonia, chronic hypersalivation, dyskinesias in PD patients receiving levodopa-based therapy, and Includes approved treatment for drug-induced extrapyramidal reactions in adult patients. The company is developing a broad range of novel CNS product candidates, including new potential treatments for motor dysfunction in PD, epilepsy, depression and other CNS disorders.
For more information, please visit www.supernus.com.
Forward-Looking Statements
This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. These statements do not convey historical information, but rather relate to projections or potential future events based on management’s current expectations. These statements are subject to risks and uncertainties that could cause actual results to differ materially from those expressed or implied by such statements. In addition to the factors described in this press release, such risks and uncertainties include, but are not limited to, our ability to maintain and improve profitability. our ability to raise sufficient capital to fully implement our corporate strategy; Implementation of our corporate strategy. our future financial performance and projected spending; Our ability to increase the number of prescriptions for each product. our ability to increase net revenue; Our ability to commercialize products containing Qelbree. our ability to enter into future partnerships with pharmaceutical companies and academic institutions, or obtain funding from government agencies; Our product research and development activities, including the timing and progress of our clinical trials and projected spending. our ability to obtain regulatory approval to develop and commercialize our product candidates, and the timing of receipt; Our ability to protect intellectual property and operate our business without infringing the intellectual property rights of others. Our expectations regarding federal, state, and foreign regulatory requirements. the therapeutic efficacy, efficacy and safety of our product candidates; Accuracy of our estimates regarding the size and characteristics of the market likely to be addressed by the product candidate; our ability to improve our manufacturing capabilities for our products and product candidates; our projected markets and market growth; our product formulations and patient needs, and potential funding sources; Our staffing needs. Our ability to increase the number of prescriptions written for each product and Adamus’ products. our ability to increase net revenues from our products and Adamus’ products; and other risk factors as described from time to time in our filings with the Securities and Exchange Commission made pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934; We undertake no obligation to update the information in this press release to reflect events or circumstances after the date of this press release or to reflect the occurrence of anticipated or unanticipated events.
contact address:
Jack A. Hatter, President and CEO
Timothy C. Dec, Senior Vice President and CFO
Supernas Pharmaceuticals, Inc.
Phone: (301) 838-2591
Also
Investor Contact:
peter vozzo
ICR Westwick
Office: (443) 213-0505
Mobile: (443) 377-4767
Email: peter.vozzo@westwicke.com
